29.03.2012 • News

BioAmber Produces Bio-based 1,4-Butanediol

BioAmber has scaled up its hydrogenation catalyst technology under license from DuPont and converted multi-ton quantities of bio-succinic acid into 100% bio-based 1,4-butanediol (1,4-BDO), tetrahydrofuran (THF) and gamma-butyrolactone (GBL).

BioAmber believes the global addressable market for these products exceeds $4 billion, and that they are principally used to make polyesters, polyurethanes, spandex and biodegradable plastics.

Using bio-succinic acid made at its French facility as a starting material, BioAmber successfully completed a 1,4-BDO production campaign in collaboration with one of the world's leading commercial catalyst suppliers and a toll manufacturer possessing large-scale hydrogenation reactors and distillation columns.

"This is the culmination of two years of work and an important milestone in the development of our bio-based 1,4-BDO platform. We have been able to couple the DuPont catalyst technology with our bio-succinic acid production to manufacture high purity bio-based 1,4-BDO at demonstration scale," Jim Millis, BioAmber's Chief Technology Officer said. "We are developing an integrated plant engineering design that combines the production of bio-succinic acid and bio-based 1,4-BDO on a single site," he added.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read